These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 38100144)
21. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer. Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425 [TBL] [Abstract][Full Text] [Related]
22. Private Equity In Dermatology: Effect On Price, Utilization, And Spending. Braun RT; Bond AM; Qian Y; Zhang M; Casalino LP Health Aff (Millwood); 2021 May; 40(5):727-735. PubMed ID: 33939519 [TBL] [Abstract][Full Text] [Related]
23. Urologists' self-referral for pathology of biopsy specimens linked to increased use and lower prostate cancer detection. Mitchell JM Health Aff (Millwood); 2012 Apr; 31(4):741-9. PubMed ID: 22492891 [TBL] [Abstract][Full Text] [Related]
24. Physician and facility drivers of spending variation in locoregional prostate cancer. Rodin D; Chien AT; Ellimoottil C; Nguyen PL; Kakani P; Mossanen M; Rosenthal M; Landrum MB; Sinaiko AD Cancer; 2020 Apr; 126(8):1622-1631. PubMed ID: 31977081 [TBL] [Abstract][Full Text] [Related]
25. Driving forces and current trends in private equity acquisitions within ophthalmology. Del Piero J; Parikh R; Weng CY Curr Opin Ophthalmol; 2022 Sep; 33(5):347-351. PubMed ID: 35838270 [TBL] [Abstract][Full Text] [Related]
26. Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance. Macleod LC; Yabes JG; Fam MM; Bandari J; Yu M; Maganty A; Furlan A; Filson CP; Davies BJ; Jacobs BL Eur Urol Focus; 2020 Mar; 6(2):242-248. PubMed ID: 31031042 [TBL] [Abstract][Full Text] [Related]
27. Association Between Hospital Private Equity Acquisition and Outcomes of Acute Medical Conditions Among Medicare Beneficiaries. Cerullo M; Yang K; Joynt Maddox KE; McDevitt RC; Roberts JW; Offodile AC JAMA Netw Open; 2022 Apr; 5(4):e229581. PubMed ID: 35486398 [TBL] [Abstract][Full Text] [Related]
28. Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees. Marchetti KA; Oerline M; Hollenbeck BK; Kaufman SR; Skolarus TA; Shahinian VB; Caram MEV; Modi PK Urology; 2021 Sep; 155():77-82. PubMed ID: 33610652 [TBL] [Abstract][Full Text] [Related]
29. United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region. McNaughton Collins M; Barry MJ; Zietman A; Albertsen PC; Talcott JA; Walker Corkery E; Elliott DB; Fowler FJ Urology; 2002 Oct; 60(4):628-33. PubMed ID: 12385923 [TBL] [Abstract][Full Text] [Related]
30. Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations. Modi PK; Kaufman SR; Borza T; Yan P; Miller DC; Skolarus TA; Hollingsworth JM; Norton EC; Shahinian VB; Hollenbeck BK Cancer; 2018 Aug; 124(16):3364-3371. PubMed ID: 29905943 [TBL] [Abstract][Full Text] [Related]
31. Understanding Active Surveillance for Prostate Cancer. Lai LY; Shahinian VB; Oerline MK; Kaufman SR; Skolarus TA; Caram MEV; Hollenbeck BK JCO Oncol Pract; 2021 Nov; 17(11):e1678-e1687. PubMed ID: 33830822 [TBL] [Abstract][Full Text] [Related]
32. Differences between urologists in the United States and Canada in the approach to prostate cancer. Fleshner N; Rakovitch E; Klotz L J Urol; 2000 May; 163(5):1461-6. PubMed ID: 10751858 [TBL] [Abstract][Full Text] [Related]
33. Recent Trends in Private Equity Acquisition of Orthopaedic Practices in the United States. Boddapati V; Danford NC; Lopez CD; Levine WN; Lehman RA; Lenke LG J Am Acad Orthop Surg; 2022 Apr; 30(8):e664-e672. PubMed ID: 35077400 [TBL] [Abstract][Full Text] [Related]
34. Contemporary Management of Incident Prostate Cancer in Large Community Urology Practices in the United States. Shelton JB; Buffington P; Augspurger R; Gaylis F; Cohen T; Mehlhaff B; Suh R; Bradford TJ; Kwan L; Koo AS; Shore N Urology; 2019 Jul; 129():79-86. PubMed ID: 30954610 [TBL] [Abstract][Full Text] [Related]
35. Differences in treatment choices for localised prostate cancer diagnosed in private and public health services. Te Marvelde L; Milne RL; Hornby CJ; Chapman AB; Giles GG; Haines IE Med J Aust; 2020 Nov; 213(9):411-417. PubMed ID: 32996611 [TBL] [Abstract][Full Text] [Related]
36. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC; Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890 [TBL] [Abstract][Full Text] [Related]
38. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Fowler FJ; Bin L; Collins MM; Roberts RG; Oesterling JE; Wasson JH; Barry MJ Am J Med; 1998 Jun; 104(6):526-32. PubMed ID: 9674714 [TBL] [Abstract][Full Text] [Related]
39. Perceptions of gender equity in pediatric urology. Haslam RE; Collins A; Martin LH; Bassale S; Chen Y; Seideman CA J Pediatr Urol; 2021 Jun; 17(3):406.e1-406.e7. PubMed ID: 33558178 [TBL] [Abstract][Full Text] [Related]
40. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries. MacLennan S; Azevedo N; Duncan E; Dunsmore J; Fullwood L; Lumen N; Plass K; Ribal MJ; Roobol MJ; Nieboer D; Schouten N; Skolarus TA; Smith EJ; N'Dow J; Mottet N; Briganti A; Eur Urol; 2023 May; 83(5):393-401. PubMed ID: 36639296 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]